Pfizer is investing $120 million in a Kalamazoo facility to produce a treatment for COVID-19. The officer of Governor Gretchen Whitmer has released the following:
Today, Governor Whitmer joined Pfizer Inc. in announcing that it will further strengthen its commitment to Michigan manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVID, which will create more than 250 additional high-skill jobs at Pfizer’s Kalamazoo site. This investment builds on Governor Whitmer’s commitment to growing Michigan’s economy and creating good-paying jobs for Michiganders across the state.
“Pfizer’s $120 million expansion in Kalamazoo creating 250 good-paying jobs making PAXLOVID will save lives and build on Michigan’s economic momentum,” said Governor Gretchen Whitmer. “Pfizer’s Kalamazoo facility also made some of the first doses of the vaccine, and now this proud Michigan company will play a critical role in both the treatment and prevention of COVID. By creating opportunity for Michiganders, Pfizer is helping us grow our economy, create good-paying jobs, and keep families safe.”
This investment is another step in Pfizer’s effort to bring more key biopharmaceutical manufacturing to the U.S., increasing Pfizer’s capability to produce and supply treatments and medicines for patients in the U.S. and around the world.
“Pfizer Global Supply has made the impossible possible, making billions of vaccine doses and now millions of treatment courses to help battle the deadly COVID-19 pandemic,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “By increasing production at our Michigan facility, we are both helping patients around the world and expanding important manufacturing innovation to the U.S. This investment builds upon our $5 billion of investments across our manufacturing and distribution portfolio since 2017 to support the ongoing growth of U.S. manufacturing leadership.”
To date, Pfizer has manufactured over 5.5 million packs of PAXLOVID globally across 26 countries, including 1.3 million courses shipped to the U.S. The significant investment will allow Pfizer to increase supply capacity for PAXLOVID as needed to help meet global demand. With this new investment, Kalamazoo will be among the world’s largest producers of active pharmaceutical ingredient (API), with the capacity to produce 1,200 metric tons annually.
Pfizer also plans to expand its Modular Aseptic Processing (MAP) sterile injectable pharmaceutical production facility in Kalamazoo with a phase two investment. The expansion adds to the initial investment of $450 million in phase one to build a 400,000-square-foot production facility and further establishes Kalamazoo as one of the most technically advanced sterile injectable pharmaceutical production facilities in the world.
“Pfizer’s Kalamazoo facility has been at the forefront of pharmaceutical manufacturing for more than 135 years through the legacy company Upjohn,” said Mike McDermott, Chief Global Supply Officer, Pfizer. “The Kalamazoo facility uses some of our most innovative manufacturing technology and has been essential in Pfizer’s fight against COVID-19, producing more than one billion doses of COVID-19 vaccine at the site to date. Through this expansion, we will continue to invest in the next generation of manufacturing and supply chain resilience.”
